Lecanemab’s main action depends on its Fc fragment calling microglia into action: recent work from VIB and KU Leuven shows the Fc is essential for microglia to engulf and digest amyloid beta, and removing that fragment abolishes plaque clearance. That mechanism explains why the drug reduces smaller, soluble amyloid forms (and Aβ42/Aβ38 levels) but produces only modest clinical slowing while carrying measurable safety and cost trade-offs.
How the Fc fragment drives plaque removal in humanized models
Researchers implanted human microglia into Alzheimer’s mouse models and tracked responses with single-cell transcriptomics; the Fc portion of lecanemab engages microglial receptors, triggers lysosomal programs and enables phagocytosis, rather than simply neutralizing plaques by binding. In those experiments, antibodies lacking the Fc fragment failed to activate the clearance genes and produced no measurable drop in amyloid pathology, which is a concrete mechanistic correction to the idea that lecanemab works by passive binding alone.
Who is likely to get the expected benefit — and who may not
Lecanemab preferentially removes smaller, soluble and protofibrillar amyloid species, so starting treatment in early disease stages (mild cognitive impairment or very early Alzheimer’s) increases the chance that microglia can clear toxic forms before larger insoluble deposits dominate. Models without functional microglia showed no plaque clearance, implying that patients with impaired brain immune responses—due to age, comorbidity, or unknown genetic variants—may derive less benefit or require different strategies to prime microglia first.
Risks, monitoring rules and practical thresholds
The drug’s safety profile includes amyloid‑related imaging abnormalities (ARIA): cerebral edema and cerebral microhemorrhages observed in trials and real-world use, which drives a clear monitoring and stop-signal protocol. Regulators have acted accordingly — the FDA gave full approval in 2023, yet some systems such as the UK’s NHS restrict coverage because of cost-effectiveness and ARIA concerns — so clinical programs typically require pre-treatment genetic testing (to assess APOE-related risk), baseline MRI, and repeated imaging to detect ARIA early.
| Item | Why it matters | Action / threshold |
|---|---|---|
| Fc-dependent mechanism | Clearing requires microglial activation; no Fc → no clearance | Consider patient microglial health; experimental combos may be needed if microglia dysfunctional |
| ARIA (edema, microbleeds) | Major safety driver in trials and post-approval monitoring | Baseline MRI + periodic MRI; pause or stop for symptomatic ARIA or significant radiographic worsening |
| Stage of disease | More clearance of smaller/protofibrillar amyloid suggests early start is more effective | Candidate = early AD / MCI with confirmed amyloid pathology; avoid late-stage expectations |
| Cost and coverage | High annual cost has limited adoption in some health systems | Check payer rules (e.g., NHS limits); discuss out-of-pocket and realistic benefit with patients |
Deciding, starting and when to pause or stop
Start only after confirming amyloid pathology and discussing realistic goals: trials showed biomarker reductions (including lower insoluble Aβ42 and Aβ38) and a slowing of decline, but the clinical effect size is modest, so the decision weighs expected small gains against ARIA risk and cost. A practical threshold to stop or pause is the emergence of symptomatic ARIA or significant radiographic progression of edema/bleeding on follow-up MRI; persistent cognitive decline despite biochemical amyloid reductions is another signal to reassess the plan rather than continue indefinitely.
Because the Fc‑microglia interaction is central, future strategies may prefer agents that modulate microglial function directly or alter Fc properties to keep clearance while reducing ARIA; for now, clinicians should prioritize early-stage patients with intact immune function, arrange APOE/genetic testing ahead of dosing, and schedule MRI checkpoints that align with local protocols and insurer requirements.
Quick Q&A
Does lecanemab work just by binding plaques? No — VIB and KU Leuven data show the Fc fragment is required to activate microglia and lysosomal degradation; binding alone is insufficient.
Who should get tested before treatment? Genetic testing (commonly for APOE status) and baseline MRI are recommended to stratify ARIA risk and establish a monitoring baseline.
When should treatment be paused or stopped? Pause or stop for symptomatic ARIA or new/worsening MRI findings; also reassess if cognitive decline continues despite biomarker improvement.